Sandra A. Carson, MD
Editor: Sexuality, Reproduction and Menopause
Professor of Obstetrics and Gynecology
Warren Alpert Medical School of Brown University
Director of the Division of Reproductive Endocrinology and Infertility
Women & Infants Hospital of Rhode Island
Providence, Rhode Island
Valerie L. Baker, MD
Medical Director
Stanford Fertility & Reproductive Medicine Center
Stanford, California
James H. Liu, MD
Arthur H. Bill Professor and Chair
Departments of Reproductive Biology and Obstetrics & Gynecology
Case Western Reserve Medical School
University Hospitals Case Medical Center
Cleveland, Ohio
Susan Wysocki, RN, WHNP, FAANP
Women’s Health Nurse Practitioner
President and Chief Executive Officer
National Association of Nurse Practitioners in Women’s Health
Washington, District of Columbia
RELEASE DATE: August 1, 2008 EXPIRATION DATE: July 31, 2009 ESTIMATED TIME TO COMPLETE ACTIVITY: 1.0 hoursTARGET AUDIENCEThis activity has been designed to meet the educational needs of health professionals who care for women from adolescence to postmenopause.EDUCATIONAL OBJECTIVESAt the conclusion of the educational activity, participants should be able to:
• Discuss the potential effects and implications that progestins or progesterone have on the endometrium
• Distinguish differences among synthetic progestins and progesterone, with varying side-effect profiles and methods of administration
• Explain to patients how benefits and risks may affect them individually, based on their unique profile, before drawing conclusions or recommending hormone therapyACCREDITATION STATEMENTThe American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.CREDIT DESIGNATION STATEMENTThe American Society for Reproductive Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.It is the policy of the ASRM to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors participating in this activity are expected to disclose any relationships they may have with companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. The content and views presented in this activity are those of the faculty/authors and do not necessarily reflect those of the ASRM or Solvay Pharmaceuticals, Inc. Any discussion of off-label, experimental, or investigational use of drugs or devices will also be disclosed. The disclosure statements were reviewed by the Subcommittee for Standards of Commercial Support of the CME Committee of ASRM and any perceived conflicts of interest were resolved in accordance with the policies of the ACCME.DISCLOSURE• Dr Valerie L. Baker reports that she has received a grant/research support from IBSA.
• Dr Sandra A. Carson reports that she has served as a consultant for Watson Labs and Columbia Research Labs and served on the speakers’ bureau of Ther-Rx.
• Dr James H. Liu reports that he served as a consultant to Barr, Solvay and Novogyne and received a grant/research support from Barr-Duramed, Solvay, and Procter & Gamble.
• Ms Susan Wysocki reports that she has served on the advisory boards of Ortho Women’s Health, Bayer HealthCare, Digene, Duramed, Lilly, Wyeth, Merck, and Upsher-Smith. She has also served on the speakers’ bureau of Bayer HealthCare, Duramed, Organon, Wyeth, and Ther-Rx.There may be discussion of off-label or otherwise nonapproved uses of products and/or devices.
PDF version of this article
